Coenzyme Q10, ST Segment Elevation Myocardial Infarction (STEMI)
Conditions
Keywords
coenzyme Q10, Acute Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI), Global Longitudinal Strain, Ubiquinone, Primary Percutaneous Coronary intervention, Cardiovascular disease
Brief summary
Left ventricular remodeling can still occur after primary percutaneous coronary intervention (PCI). Global longitudinal strain (GLS) assessment has been used as a predictor of left ventricular remodeling. Coenzyme Q10 is known for its anti-inflammatory and antioxidant properties, which may help reduce cardiac remodeling. This study aims to determine the effect of CoQ10 administration after myocardial infarction as an adjunct to standard therapy on left ventricular remodeling, assessed through changes in GLS values. Researchers will compare Coenzyme Q10 to a placebo to see if Coenzyme Q10 has a greater effect on improving left ventricular GLS values in patients with ST-Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention.
Detailed description
This is a randomized, double blind study with 2 treatment groups. Participants diagnosed with Acute STEMI post primary PCI who meet the inclusion criteria and no exclusion criteria are given an explanation regarding the research and additional therapy that will be given, then informed consent is requested. Participants will be randomized to one of the two treatment groups by chance. Patients randomized to the first group will receive coenzyme Q10 100mg/12hours. Patients randomized to the other treatment group will receive a placebo. It is expected that the patients of the treatment group with the coenzyme Q10 will have a greater improvement of their GLS.
Interventions
DRUGCoenzyme Q 10
participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
DRUGPlacebo
participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
Sponsors
Universitas Diponegoro
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
participant, care Provider, and investigator will not know either they include in treatment or control group
Intervention model description
This research is an experimental clinical study with a double blinded randomized controlled trial design. The study group consisted of patients with acute STEMI underwent primary PCI. The first group was patients who received standard treatment plus coenzyme Q10 100mg / 12 hours orally for up to 8 weeks (group A). Meanwhile, the second group was patients who received standard treatment plus placebo for up to 8 weeks (group B).
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 21 - 80 years * Agree to participate in the study * Patients with a diagnosis of Acute Myocardial Infarction with ST-Segment Elevation (AMI-STE) with onset \< 12 hours who underwent primary percutaneous coronary intervention (PCI) * Successful primary PCI on the culprit lesion (residual stenosis \< 20%, TIMI flow III) * Received standard medication therapy according to guidelines (Guideline-Directed Medical Therapy; GDMT) achieved during hospitalization * Sinus rhythm at the time of echocardiographic examination
Exclusion criteria
* Patients who routinely consume CoQ10 prior to the study * Patients with hemodynamic conditions of Killip class III-IV and NYHA class III-IV * Patients with a history of previous acute myocardial infarction * Patients with a history of previous PCI or fibrinolytic therapy * Patients with a history of previous coronary artery bypass surgery * Patients with heart valve disease greater than moderate severity * Patients receiving warfarin therapy * Patients with a diagnosis of isolated right ventricular infarction * Patients with inadequate echocardiographic image quality (poor echo window)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvements in Global longitudinal strain | at 8 weeks follow up | GLS value was evaluated pre and post intervention. Pre intervention GLS were examined within the first 24 hour after PPCI, GLS post intervention at 8 weeks follow up GLS assesed with Epiq 7C ultrasound machine manufactured by Philips Medical Systems, the investigators conducted two-dimentional speckle-tracking investigations. These studies utilized QLAB/automated cardiac motion quantification (ACMQ) version 10.85 and QLAB/LV auto-strain version 12.0, both developed by Philips Healthcare. Three sequential cardiac cycles of apical 4, 2, and 3 chamber view images were stored using all scanners with the best machine settings and frame rates 50-70 frames per second for the purpose of measuring strain using speckle tracking echocardiography. |
Countries
Indonesia
Outcome results
None listed